Baxter International Inc. Stock price

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-18 pm EDT 5-day change 1st Jan Change
41.54 USD -0.17% Intraday chart for Baxter International Inc. -4.46% +7.45%
Sales 2024 * 15.11B Sales 2025 * 15.68B Capitalization 21.1B
Net income 2024 * 747M Net income 2025 * 960M EV / Sales 2024 * 2.01 x
Net Debt 2024 * 9.24B Net Debt 2025 * 8.14B EV / Sales 2025 * 1.86 x
P/E ratio 2024 *
22.1 x
P/E ratio 2025 *
18.4 x
Employees 60,000
Yield 2024 *
2.72%
Yield 2025 *
3.01%
Free-Float 74.01%
More Fundamentals * Assessed data
Dynamic Chart
Baxter International Receives a Shareholder Proposal from John Chevedden CI
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data RE
Baxter International Now Considering Sale of Kidney Care Business to Private Equity Investors MT
Dialysis firms gain as Ozempic kidney trial data disappoints RE
Transcript : Baxter International Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 04:00 PM
Baxter International Provides an Update on the Planned Separation of its Kidney Care Business CI
Transcript : Baxter International Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 11:00 AM
Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years MT
Spectral Medical Announcing "Major Milestone" by Reaching Its Interim Enrollment Target of 90 Patients MT
Baxter International Maintains Quarterly Dividend at $0.29 a Share, Payable April 1 to Shareholders of Record March 1 MT
Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024 CI
UBS Adjusts Baxter International Price Target to $42 From $40, Maintains Neutral Rating MT
Deutsche Bank Adjusts Baxter International Price Target to $42 From $35, Maintains Hold Rating MT
Correction: Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1, 2024 Earnings Forecasts MT
Correction: Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1 and 2024 Earnings Outlook; Shares Drop MT
More news
1 day-0.17%
1 week-5.09%
Current month+1.52%
1 month+0.78%
3 months+7.34%
6 months+6.29%
Current year+7.45%
More quotes
1 week
41.24
Extreme 41.24
43.37
1 month
40.27
Extreme 40.27
44.01
Current year
37.87
Extreme 37.87
44.01
1 year
31.01
Extreme 31.01
50.21
3 years
31.01
Extreme 31.01
89.70
5 years
31.01
Extreme 31.01
95.19
10 years
31.01
Extreme 31.01
95.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 15-09-30
Director of Finance/CFO 54 23-10-17
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-05
Director/Board Member 64 22-05-09
Director/Board Member 64 19-02-17
More insiders
Date Price Change Volume
24-03-18 41.54 -0.17% 2,697,336
24-03-15 41.61 -0.98% 5,489,356
24-03-14 42.02 -1.55% 3,795,705
24-03-13 42.68 -0.49% 3,851,996
24-03-12 42.89 -1.36% 3,648,644

Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT

More quotes
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (35.7%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (24.8%); - systems for delivering medications and intravenous therapy (19.1%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.4%). Net sales are distributed geographically as follows: the United States (47.8%), Europe/Middle East/Africa (24.5%), Asia/Pacific (18.2%), Latin America and Canada (9.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
41.54 USD
Average target price
47.2 USD
Spread / Average Target
+13.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Baxter International Inc. - Nyse